Daily Archives: October 2, 2013
Alabama and other states are slow to join federal programs aimed at getting young people care they need at home
Paul Boyd has two lives.
In one life, Boyd is a graduate student in counseling at the University of Montevallo, a small liberal-arts school about 30 minutes from where he lives. After class he sometimes sits on the porch of a coffee shop talking with a group of locals and college students.
In his other life, the 37-year-old Boyd is a resident of Chandler Health and Rehab, a nursing home in Alabaster, Ala. He drives the hallways in his sip-and-puff wheelchair, chatting with older residents like Thelma, who clutches a plastic baby doll to her chest.
NEWARK, Calif., Oct. 2, 2013 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM) announced today that the U.S. Food and Drug Administration (FDA) has authorized the Company’s Investigational New Drug (IND) application for clinical testing of the Company’s proprietary HuCNS-SC® human neural stem cells as a treatment for spinal cord injury. As a first action under this IND, the Company is working to open U.S. sites for its Phase I/II clinical trial for chronic spinal cord injury, which is currently underway in Switzerland and Canada.